Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Active, not recruiting, industry sponsors, Kidney and urology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed288
11 trials
Showing 1 to 11, recently updated first.
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With HyperphosphatemiaPivotal-lookingActive, not recruiting
R1 TherapeuticsIndustry
NCT06712654 · 168 participants (planned) · Start Jun 1, 2026 · Primary completion Feb 28, 2027
Drug: AP306 75 mg BID; AP306 125 mg BID and 6 more · For: Hyperphosphatemia; Chronic Kidney Disease Requiring Chronic Dialysis; End Stage Renal Disease on Dialysis
Sites: Huntsville, Alabama; Chula Vista, California; Los Angeles, California · 31 sites in all
- Monthly Dosing of Atacicept in IgANActive, not recruiting
Vera Therapeutics, Inc.Industry
NCT07020923 · 90 participants (planned) · Start May 29, 2025 · Primary completion Sep 22, 2026
Drug: Atacicept · For: IgA Nephropathy (IgAN); Berger Disease
Sites: Brisbane, California
- Phase 2b Open-Label Repeat Kidney Biopsy StudyActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06740526 · 56 participants · Start Dec 5, 2024 · Primary completion Dec 28, 2028
Drug: Sibeprenlimab · For: IgA Nephropathy
Sites: Birmingham, Alabama; Stanford, California; Denver, Colorado · 19 sites in all
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruiting
Alpine Immune Sciences, Inc.Industry
NCT05732402 · 72 participants · Start Mar 15, 2023 · Primary completion Mar 2, 2028
Drug: Povetacicept · For: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Valencia, California · 30 sites in all
- A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyActive, not recruiting
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT07305974 · 30 participants (planned) · Start Sep 8, 2025 · Primary completion Mar 31, 2029
Drug: RG002C0106; placebo subcutaneous administration · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
- A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruiting
Suzhou Sanegene Bio Inc.Industry
NCT06786338 · 45 participants · Start Jun 6, 2025 · Primary completion Dec 29, 2026
Drug: SGB-9768 · For: IgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGN
Sites: Beijing, China; Changsha, China; Chengdu, China · 11 sites in all
- A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06942910 · 224 participants · Start May 7, 2025 · Primary completion Sep 26, 2026
Drug: Zibotentan/Dapagliflozin; Dapagliflozin · For: Chronic Kidney Disease With High Proteinuria
Sites: Aramil, Russia; Izhevsk, Russia; Krasnoyarsk, Russia · 14 sites in all
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07222917 · 222 participants · Start Dec 5, 2025 · Primary completion Dec 10, 2026
Drug: Baxdrostat/dapagliflozin; Baxdrostat/Placebo · For: Chronic Kidney Disease and Hypertension
Sites: Surprise, Arizona; Hollywood, Florida; Port Charlotte, Florida · 55 sites in all
- A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)Pivotal-lookingActive, not recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07716618 · 320 participants (planned) · Start Jan 17, 2025 · Primary completion May 27, 2026
Drug: SAL0120 1mg; SAL0120 2mg and 2 more · For: Chronic Kidney Disease
Sites: Chengdu, China
- A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)Active, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05092347 · 43 participants · Start Aug 2, 2022 · Primary completion Nov 22, 2027
Drug: Vonsetamig · For: Chronic Kidney Disease (CKD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 10 sites in all
- Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04573920 · 103 participants · Start Mar 15, 2021 · Primary completion Jul 2, 2024
Drug: Atrasentan · For: IgA Nephropathy; Focal Segmental Glomerulosclerosis; Alport Syndrome and 3 more
Sites: Glendale, California; Los Angeles, California; San Dimas, California · 33 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.